

# Status Epilepticus and Refractory Status Epilepticus Management

Nicholas S. Abend, MD,<sup>\*,†</sup> David Bearden, MD,<sup>\*,†</sup> Ingo Helbig, MD,<sup>\*,†</sup>  
Jennifer McGuire, MD,<sup>\*,†</sup> Sona Narula, MD,<sup>\*,†</sup> Jessica A. Panzer, MD, PhD,<sup>\*,†</sup>  
Alexis Topjian, MD, MSCE,<sup>‡</sup> and Dennis J. Dlugos, MD<sup>\*,†</sup>

Status epilepticus (SE) describes persistent or recurring seizures without a return to baseline mental status and is a common neurologic emergency. SE can occur in the context of epilepsy or may be symptomatic of a wide range of underlying etiologies. The clinician's aim is to rapidly institute care that simultaneously stabilizes the patient medically, identifies and manages any precipitant conditions, and terminates seizures. Seizure management involves "emergent" treatment with benzodiazepines followed by "urgent" therapy with other antiseizure medications. If seizures persist, then refractory SE is diagnosed and management options include additional antiseizure medications or infusions of midazolam or pentobarbital. This article reviews the management of pediatric SE and refractory SE. *Semin Pediatr Neurol* 21:263-274 © 2014 Elsevier Inc. All rights reserved.

## Introduction

Status epilepticus (SE) describes a prolonged seizure or recurrent seizures without a return to baseline. It is the most common pediatric neurologic emergency with an incidence of 18-23 per 100,000 children per year.<sup>1</sup> Care involves simultaneously identifying and managing systemic complications, identifying and managing precipitant etiologies, and administering anticonvulsants to terminate ongoing seizures(s).

Historically, SE was defined as a seizure lasting longer than 30 minutes or a series of seizures without return to baseline level of alertness between seizures.<sup>2</sup> During the prodromal or incipient stage (<5 minutes), it is unknown

whether the seizure will self-terminate or evolve into SE. Persisting SE has been divided into early SE (5-30 minutes), established SE (>30 minutes), or refractory SE (RSE) (seizures persist despite treatment with adequate doses of 2 or 3 anticonvulsants). Owing to increasing recognition that most seizures are brief (3-4 minutes)<sup>3</sup> and anticonvulsant administration delays are associated with more refractory seizures, the temporal definition of SE has gradually shortened and the related terminology has been modified to convey a greater sense of urgency. The Neurocritical Care Society guideline for SE management in children and adults defines SE as "5 minutes or more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures" and opines that "definitive control of SE should be established within 60 minutes of onset."<sup>4</sup> Rather than labeling medications as first-, second-, and third-line agents, which provide no sense of timing urgency, the guideline uses the terms "emergent," "urgent," and "refractory" to help convey that medications should be administered sequentially and rapidly. RSE is defined as clinical or electrographic seizures that persist after administration of an adequate dose of an initial benzodiazepine and a second appropriate antiseizure medication; in contrast to prior definitions, no specific time must elapse before initiation of RSE management.

Variability in SE management and treatment delays are common. Studies of SE management in children in emergency departments have described that laboratory

From the \*Department of Neurology, The Children's Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

†Department of Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

‡Department of Anesthesia and Critical Care Medicine, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

Nicholas Abend is funded by NIH, USA K23-NS076550. Alexis Topjian is funded by NIH, USA K23-NS075363. Jessica Panzer and Jennifer McGuire are funded by NIH, USA K12-NS049453. Dennis Dlugos is funded by NIH, USA, Grant nos. 1R01NS053998, 2U01NS045911, 1R01LM011124, and U01NS077276.

Address reprint requests to Nicholas Abend, MD, CHOP Neurology, 3501 Civic Center Blvd, Philadelphia, PA 19104. E-mail: [abend@email.chop.edu](mailto:abend@email.chop.edu)

parameters were often not checked and some results were only available after long delays,<sup>5</sup> the median time to administer a second-line anticonvulsant to a seizing child was 24 minutes,<sup>6</sup> and that benzodiazepine dosing was outside usual dosing guidelines in 23% of children with SE.<sup>5</sup> Excess benzodiazepine dosing (which often occurs when prehospital doses are administered) contributes to respiratory insufficiency and need for intensive care unit (ICU) admission,<sup>5,7,8</sup> whereas inadequate dosing may reduce the likelihood of seizure termination. Several studies have described associations between SE management delays and more prolonged seizures<sup>9</sup> as well as lower anticonvulsant responsiveness.<sup>10-13</sup> To expedite therapeutic decisions, a consensus document recommended that all units have a written management pathway with a clear structured time frame.<sup>14</sup> An example SE management pathway is provided in Table 1, which is adapted from the Neurocritical Care Society guideline<sup>4</sup> and other recent publications.<sup>15-17</sup>

## Medical Management and Precipitating Etiology Evaluation

Medical stabilization of a patient with acute seizures should focus on airway, breathing and circulation with the goal to maintain oxygenation, ventilation, and adequate tissue perfusion while rapidly diagnosing and treating the seizure precipitant. The Neurocritical Care Society guideline provides a timed treatment outline.<sup>4</sup> Steps to be completed in the initial 2 minutes include noninvasive airway protection and gas exchange with head positioning and vital sign assessment. Steps to be included in the initial 5 minutes include neurologic examination and placement of peripheral intravenous access for administration of emergent antiseizure medication therapy and fluid resuscitation. Steps to be completed in the initial 10 minutes include intubation if airway or gas exchange is compromised or intracranial pressure is elevated. Intubation may be necessary because of seizure-associated hypoventilation, medication-associated hypoventilation, inability to protect the airway, or other causes of oxygenation or ventilation failure. Steps to be completed in the initial 15 minutes include vasopressor support if needed.<sup>4</sup>

Multiple studies have characterized the various potential etiologies for SE.<sup>1,18-20</sup> The most common cause of pediatric SE is febrile SE, and SE may also occur in children with epilepsy.<sup>21</sup> However, in most situations, acute precipitating conditions must be considered. Acute symptomatic conditions are identified in 15%-20% of children with SE.<sup>1,19,22</sup> The American Academy of Neurology practice parameter addressing the diagnostic assessment of a child with convulsive SE reported that abnormal results among children who underwent testing included low anticonvulsant levels (32%), neuroimaging abnormalities (8%), electrolyte imbalances (6%), inborn errors of metabolism (4%), ingestion (4%), central nervous system infections (3%), and positive blood cultures (3%).<sup>23</sup> Rapidly reversible causes of seizures should be diagnosed and treated rapidly upon of hospital

arrival, specifically evaluating for electrolyte disturbances such as hyponatremia, hypoglycemia, hypomagnesemia, and hypocalcemia. The Neurocritical Care Society guideline provides suggestions regarding etiologic testing, including assessment of bedside finger stick blood glucose (0-2 minutes) and serum glucose, complete blood count, basic metabolic panel, calcium, magnesium, and antiseizure medication levels (5 minutes). In some patients, other diagnostic testing may include neuroimaging or lumbar puncture (LP) (0-60 minutes), additional laboratory testing (including liver function tests, coagulation studies, arterial blood gas, toxicology screen, and inborn errors of metabolism screening), and continuous electroencephalographic (EEG) monitoring if the patient is not waking up after clinical seizures cease (15-60 minutes).<sup>4</sup> These recommendations are similar to those of the prior American Academy of Neurology practice parameter.<sup>23</sup> Rarer infectious, metabolic, autoimmune, and paraneoplastic etiologies may be considered in specific situations.<sup>24</sup>

Neuroimaging abnormalities have been reported in 30% of children with SE and described to alter acute management in 24%.<sup>19</sup> If no etiology is identified by computerized tomography (CT), magnetic resonance imaging (MRI) may still identify lesions. One study described that, among 44 children who underwent head CT and MRI, 14 showed normal findings on head CT but abnormal findings on MRI, leading to the conclusion that MRI had a superior yield and should be considered whenever available if head CT is nondiagnostic.<sup>19</sup>

There are two main urgent EEG indications. First, if the diagnosis of psychogenic SE is suspected, then rapid diagnosis using EEG monitoring may avoid continued exposure to anticonvulsants with potential adverse effects. Second, if there is concern that EEG-only (nonconvulsive) seizures are ongoing despite cessation of clinically evident seizures, then EEG monitoring may be required for identification and to assess the effect of continued management.<sup>25,26</sup> A multicenter study of children who underwent EEG monitoring while in the ICU reported that 33% of 98 children who presented with convulsive SE had electrographic seizures. The seizure burden was often high with electrographic SE in 47%. Further, 34% of children with seizures had exclusively EEG-only seizures, which would not have been identified without EEG monitoring.<sup>27</sup> Observational studies have reported that in multivariable analyses aiming to account for encephalopathy etiology and severity, high electrographic seizure burdens in critically ill children are associated with worse outcomes.<sup>26,28-31</sup> The Neurocritical Care Society guideline states that, to identify electrographic seizures, "continuous electroencephalographic monitoring should be initiated within one hour of SE onset if ongoing seizures are suspected" and that the management goal should be termination of both convulsive and electrographic seizures.<sup>4</sup> Further study is needed to determine whether efforts to identify and manage these electrographic seizures improve patient outcomes.

If no etiology is identified by the initial testing, then additional testing may be indicated. A targeted approach

**Table 1 Status epilepticus evaluation and management pathway. (Adapted from Abend and Loddenkemper<sup>15,16</sup> and Abend et al.<sup>17</sup>)**

<p><b>Immediate Management</b></p> <p>Non-invasive airway protection and gas exchange with head positioning positioning if needed.</p> <p>Monitor oxygen saturation, blood pressure heart rate, temperature.</p> <p>Finger stick blood glucose.</p> <p>Peripheral IV access.</p> <p>Medical and Neurologic examination.</p> <p>Labs including basic metabolic panel, calcium, magnesium, complete blood count, liver function tests, coagulation tests, arterial blood gas, and anticonvulsant levels.</p> <p>Evaluate for specific immediate reversible causes of seizures: hyponatremia, hypoglycemia, hypocalcemia, hypomagnesemia and malignant hypertension.</p> <p><b>Emergent Initial Therapy</b></p> <p>IV Access: Lorazepam 0.1mg/kg IV (max 4 mg) - may repeat if seizures persist.</p> <p>No IV Access: Diazepam Rectal 2-5 years 0.5mg/kg, 6-11 years 0.3mg/kg, ≥12 years 0.2g/kg (max 20mg) Midazolam Intramuscular (13-40kg = 5mg; &gt;40kg = 10mg), Intranasal (0.2mg/kg), Buccal (0.5mg/kg)</p> <p>Consider whether out-of-hospital benzodiazepines have been administered when considering how many doses to administer.</p> <p><b>Urgent Management</b></p> <p>Additional diagnostic testing as indicated:</p> <p>Lumbar puncture (opening pressure, cell count with differential, protein, glucose, gram stain and culture) Consider: oligoclonal band profile, IgG index, IgG synthesis rate, fungal culture, herpes simplex virus 1/2 PCR enterovirus PCR, parechovirus PCR</p> <p>Imaging: computerized tomography, magnetic resonance imaging Consider: toxicology lab, inborn errors of metabolism, anti-thyroid peroxidase antibodies, anti-thyroglobulin antibodies, bacterial cultures</p> <p>Consider EEG monitoring to evaluate for psychogenic SE or persisting EEG-only seizures after convulsive SE terminates. Neurology Consultation</p> <p><b>Urgent Control Therapy</b></p> <p>Phenytoin 20mg/kg IV (may give another 10mg/kg if needed) OR Fosphenytoin 20 PE/kg IV (may given another 10 PE/kg if needed) PE = phenytoin equivalents OR consider phenobarbital, valproate sodium, or levetiracetam.</p> <p>If &lt; 2 years, consider pyridoxine (100mg IV).</p> <p><b>Refractory Status Epilepticus Management</b></p> <p>If seizure continue after benzodiazepines and a second anti-seizure medication, the patient is in refractory status epilepticus regardless of elapsed time. Continue management as plan for ICU admission/transfer and likely continuous EEG monitoring.</p> <p>Administer another Urgent Control anticonvulsant or proceed to pharmacologic coma.</p> <p>Levetiracetam 20-60 mg/kg IV Valproate Sodium 20-40 mg/kg IV. Phenobarbital 20-40 mg/kg IV</p> <p>Pharmacologic Coma Medications</p> <p>Midazolam 0.2mg/kg bolus (max 10mg) and then initiate infusion at 0.1mg/kg/hr. Pentobarbital 5 mg/kg bolus and then initiate infusion at 0.5mg/kg/hour. For both medications, if dose escalation is needed, then re-bolus and do not just increase the infusion rate.</p> <p>Pharmacologic Coma Management</p> <p>Titrate to either seizure suppression or burst suppression based on continuous EEG monitoring. Continue pharmacologic coma for 24-48 hours. Modify anti-seizure medications so additional coverage is in place for infusion wean. Continue diagnostic testing and implementation of etiology directed therapy.</p> <p>Add-On Options</p> <p>Medications: phenytoin, phenobarbital, levetiracetam, valproate sodium, topiramate, lacosamide, ketamine, pyridoxine, pyridoxal-5-phosphate, folic acid, biotin. Other: epilepsy surgery, ketogenic diet, vagus nerve stimulator, immunomodulatory therapy (methylprednisolone, IVIG, plasma exchange), hypothermia, electroconvulsive therapy.</p>
---

may be useful for some patients, but in some cases, undergoing a full panel of tests initially may be optimal.

Central nervous system infections are a common cause of acute symptomatic SE,<sup>19</sup> accounting for 0.6%-40% of all SE

in different series.<sup>32,33</sup> In addition, SE occurs in 15% of encephalitis cases overall. Development of RSE in encephalitis has been associated with younger age, fever, the presence of a prodromal gastrointestinal illness, normal

**Table 2** Suggested Infectious Disease Evaluation for Children With Refractory Status Epilepticus (RSE)**Urgent evaluation****Cerebrospinal fluid**

- Collect up to 10-20-mL CSF for immediate analysis and freeze remainder for later testing
- Opening pressure on lumbar puncture
- White blood cell count with differential, red blood cell count, and protein and glucose levels
- Gram stain, bacterial culture, and fungal cultures (if immunocompromised)
- PCR: herpes simplex virus 1/2, enterovirus, and parechovirus (if age < 3 years)

**Serum**

- Basic studies: complete blood count with differential, electrolytes and liver function, coagulation studies
- Bacterial cultures
- Serologies: Epstein-Barr virus (VCA IgG and IgM and EBNA IgG), *Mycoplasma pneumoniae*
- Hold acute serum and collect convalescent serum 10-14 d later for paired antibody testing

**Other samples**

- Mycoplasma pneumoniae* PCR from throat swab
- Enterovirus PCR and culture of throat and stool

**Radiology**

- Magnetic resonance imaging of the brain with and without gadolinium
- Chest imaging (chest x ray or CT or both)

**If RSE persists without clear etiology for  $\geq 24$  h, consider adding****Cerebrospinal fluid**

- CSF serologies (IgM and IgG): herpes simplex virus, varicella zoster virus, human immunodeficiency virus, arboviruses (including St. Louis encephalitis virus, California encephalitis group, eastern equine encephalitis virus, western equine encephalitis virus, and West Nile virus), and lymphocytic choriomeningitis.
- Acid fast bacilli (AFB) smear and *Mycobacterium tuberculosis* culture
- PCR: Epstein-Barr virus, cytomegalovirus, human herpes virus 6, and rotavirus
- Oligoclonal bands and IgG index
- Consider repeat herpes simplex virus 1/2 testing 3-7 d after initial test if clinical suspicion remains

**Serum**

- Serologies: adenovirus, arbovirus panel (including St. Louis encephalitis virus, California encephalitis group, eastern equine encephalitis virus, western equine encephalitis virus, and West Nile virus), lymphocytic choriomeningitis, HHV6, *Borrelia* sp., *Toxoplasma gondii*, and influenza.
- Human immunodeficiency virus serology (consider RNA)
- PCR: herpes simplex virus 1/2 and varicella zoster virus

**Other samples**

- Consider: viral cultures and analysis (antigen detection and PCR) of other potentially affected body fluids (tracheal aspiration, urine, and stool) or mucosal sites (throat, nasopharynx, and rectum)
- Consider: Brain biopsy in subjects with a progressive deterioration over time despite empiric therapy

**Consider additional testing for selected patients based on exposure and travel history and other specific clinical symptoms.****Examples include but are not limited to the following**

- Culture or PCR of skin lesions if present for herpes simplex virus, varicella zoster virus, and rickettsial infection
- Naegleria fowleri* (CSF wet mount and PCR) if swimming in warm freshwater
- Bartonella* (serum) and ophthalmologic examination if exposure to cats
- Rabies serology (serum)
- Treponemal testing (serum: rapid plasma reagin [RPR] and specific treponemal test)
- Measles virus testing if unvaccinated
- Tick-borne disease testing based on geographic region (ie, *Borrelia*, *Ehrlichia*, *Rickettsia* sp., and *Anaplasma phagocytophilum* serology)
- Consider region-specific pathogens (eg, malaria based on travel history)

EBNA, Epstein-Barr virus nuclear antigen; PCR, polymerase chain reaction; VCA, viral capsid antigen.

Adapted from Venkatesan et al.<sup>35</sup> and McGuire and Greene.<sup>36</sup>

peripheral white blood cell count, and normal neuroimaging.<sup>34</sup> The clinical presentation of encephalitis and other central nervous system infections is highly variable, depending on the pathogen involved and specific host factors. In some cases, particularly in young children, individuals who

are immunocompromised or individuals who have received recent antibiotics, fever may be absent and clinical signs of infection very subtle. Therefore, LP and MRI should be performed in all cases of SE without an obvious noninfectious etiology. A diagnostic strategy to evaluate for

possible infectious etiologies is outlined in Table 2 (adapted from prior publications<sup>35,36</sup>). Detailed consideration of potential infectious etiologies may lead to focused testing and in some etiologies, specific effective treatment (such as Bartonella in cat-scratch disease).

If an autoimmune etiology for RSE is suspected, an LP should be performed to evaluate for evidence of central nervous system inflammation. Routine studies from the cerebrospinal fluid (CSF) including a cell count and protein level are useful as patients with underlying neuroinflammatory processes often have pleocytosis and elevated CSF protein level. Intrathecal immunoglobulin synthesis is a hallmark of central nervous system inflammation and should be evaluated with an oligoclonal band profile, IgG index, and IgG synthesis rate when a neuroimmune etiology is being considered. Oligoclonal bands are positive when 2 or more immunoglobulin bands are detected in the CSF but not in the accompanying serum.

Many causes of autoimmune encephalitis may be associated with neoplasm, although the frequency of tumor detection varies. Depending on the autoantibody, distinct brain regions may be targeted, with seizures or SE resulting from autoimmunity to either the limbic system or cerebral cortex.<sup>37</sup> Paraneoplastic antibodies may target intracellular antigens or antigens on the neuronal surface. Antibodies to intracellular neuronal antigens include Hu, Ma2, CV2/CRMP5, and amphiphysin; such antibodies have rates of tumor association >90%.<sup>38</sup> In general, for intracellular paraneoplastic antibodies, cytotoxic T-cell responses are believed to mediate neural inflammation and destruction, and there is poor response to immunotherapy.<sup>39</sup> An exception is encephalitis associated with anti-GAD65 antibodies. Although GAD65 is an intracellular antigen, there is less brain inflammation or destruction, a lower association with tumor (<5%), and greater response to immunotherapy.<sup>38,39</sup> Of the intracellularly targeted antibodies, anti-Hu antibodies have the strongest association with isolated seizures and limbic encephalitis, but are rarely detected in children and most often they occur in association with neuroblastoma. Patients with anti-CRMP5 antibodies may have associated chorea; whereas anti-Ma2 antibodies often result in a diencephalic syndrome, and anti-GAD65 and anti-amphiphysin, both may be associated with stiff person syndrome.<sup>40</sup>

In contrast to intracellularly targeted antibodies, disorders associated with antibodies to neuronal surface antigens have a distinct pathophysiology, as these antibodies are thought to be directly pathogenic. Antibodies bind to the target antigen at synapses and result in altered synaptic function. There is less neuronal destruction and tissue inflammation, likely resulting in the more robust responses to immunotherapy, typically with agents targeting B cells.<sup>39</sup> Of these disorders, the most well established in the pediatric population is anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, which is often associated with ovarian teratoma. This encephalitis usually begins with behavioral change or psychosis and then progresses to seizures in 70%, as well as decline of the level of consciousness,

catatonia, dyskinesias, autonomic instability, and hypoventilation.<sup>37</sup> Children comprise nearly half of identified patients, are more likely than adults to have seizure as the first presenting sign, and are less likely to have associated ovarian teratoma.<sup>41,42</sup> Antibodies against the voltage-gated potassium channel complex, which includes leucine-rich glioma-inactivated protein 1 and contactin-associated protein-like 2, are established as a cause of autoimmune epilepsy and limbic encephalitis in adults and case series of pediatric patients with likely autoimmune encephalitis have detected these antibodies in 4%-15% of subjects. In these case series, a few patients with anti-contactin-associated protein-like 2 encephalitis have been reported but no anti-leucine-rich glioma-inactivated protein 1 cases have yet been found. Similarly, although antibodies to the  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of glutamate receptor have been reported as a cause of limbic encephalitis in adults, but these have not yet been found in children.<sup>43,44</sup> Recently described autoantibodies to other synaptic proteins such as mGluR5, glycine receptors,  $\gamma$ -aminobutyric acid (GABA)-A receptors, and GABA-B receptors have been associated with seizures and RSE in children.<sup>40,45,46</sup> Reports of these antibodies remain rare, but this is an emerging field, and both the spectrum of associated diseases and number of cases are expected to grow.

As discussed previously, LP should be performed if autoimmune or paraneoplastic encephalitis is suspected. Elevated oligoclonal bands and CSF pleiocytosis support an autoimmune process with intrathecal synthesis of anti-neuronal antibodies, but these findings are not necessary for the diagnosis. Specific autoantibody testing for some of these disorders is available and should be pursued. In general, testing of CSF has superior sensitivity and specificity as compared with serum testing. Anti-NMDAR antibody testing can be performed in a number of clinical laboratories. As the most commonly identified cause of encephalitis, testing for anti-NMDAR antibodies has higher diagnostic yield than other autoantibody testing or even testing for specific viral etiologies.<sup>47,48</sup> If the test is negative or symptoms are atypical, additional autoantibody testing is commercially available with paraneoplastic autoantibody panels. In addition, any patient with known or suspected paraneoplastic disease should have appropriate tumor screening, which should include imaging of the chest and abdomen if ovarian teratoma is not detected in the pelvis.

Aside from paraneoplastic processes, Rasmussen encephalitis and Hashimoto encephalopathy are two of the most common autoimmune causes of SE. There are no specific diagnostic tests for Rasmussen encephalitis, though patients will clinically present with focal seizures and unilateral cortical deficits and are found to have progressive unilateral cortical atrophy.<sup>49</sup> If a brain biopsy is obtained, histopathology generally reveals T-cell dominated encephalitis with activated microglia.<sup>49</sup> Hashimoto encephalopathy is an acute or subacute encephalopathy that occurs most commonly in women and is associated with serum antithyroid peroxidase antibodies or antithyroglobulin antibodies. Most patients have seizures and patients with RSE have been

reported.<sup>50</sup> Anecdotal reports of patients with Hashimoto encephalopathy describe benefit with immunotherapy, and screening for antithyroid antibodies should be considered in patients with unexplained RSE.

Some genetic epilepsies may present with new-onset SE that do not produce obvious metabolic or imaging changes. Although screening for genetic epilepsies in new-onset SE is usually not considered in the acute workup, the question of an underlying genetic etiology is often considered in the subacute phase of the treatment, particularly when no other etiologies can be identified. So far, reports of patients with genetic epilepsies presenting with new-onset SE are anecdotal. Two genetic epilepsies commonly considered are epilepsies due to mutations in *SCN1A*<sup>51</sup> or *POLG1*.<sup>52</sup> Beyond the classical phenotypes of Dravet syndrome and Alpers syndrome, patients may present atypically with SE. However, in patients with severe epilepsies with new-onset SE such as febrile infection-related epilepsy syndrome (FIRES), these mutations seem to be rare.<sup>53</sup>

With increasing availability and decreasing costs of genetic testing, many genetic epilepsies are found to have a wider phenotypic spectrum than initially anticipated. Given that the genetic basis of a sizable fraction of genetic epilepsies may only be identified by parallel screening of a panel of candidate genes<sup>54</sup> or through genome-wide approaches such as exome or genome sequencing,<sup>55</sup> clinicians may consider adding either gene panel analysis or exome sequencing approaches into the systematic workflow of new-onset SE, rather than only evaluating for them during a later stage of the workup. Improving the turnaround time for genetic tests will be crucial in establishing genetic testing as a routine part of the diagnostic workflow.

## Status Epilepticus Management

The Neurocritical Care Society guideline states that “definitive control of SE should be established within 60 minutes of onset”<sup>4</sup> with termination of both clinical and electrographic seizures. Benzodiazepines are the “emergent” medications of choice; lorazepam for intravenous administration, midazolam for intramuscular or intranasal administration, and diazepam for rectal administration.<sup>4</sup> Repeat dosing may be provided in 5-10 minutes if needed. A double-blind randomized trial of 273 children with SE compared intravenous administration of lorazepam (0.1 mg/kg) and diazepam (0.2 mg/kg) in the emergency department. A half dose of either medication could be administered at 5 minutes if seizures persisted. The primary outcome was SE cessation by 10 minutes without recurrence in 30 minutes, and it was not significantly different in the 2 groups (72.1% with diazepam and 72.9% with lorazepam). Patients receiving lorazepam were more likely to be sedated (67% with lorazepam and 50% with diazepam), but there was no difference in requirement for assisted ventilation (18% with lorazepam and 16% with diazepam).<sup>56</sup> If intravenous access cannot be obtained, then providers should administer rectal, intramuscular, or buccal benzodiazepines. Providers can

consider obtaining intraosseous access if prolonged intravenous access is unable to be obtained and the patient had respiratory or circulatory instability. Care should be taken to assess whether any prehospital benzodiazepines were administered as excess may produce respiratory insufficiency.<sup>5,7,8</sup> Unless the SE etiology has been identified and definitively corrected, all children should also receive an “urgent” category anticonvulsant in addition to a benzodiazepine.<sup>4</sup>

Nearly half of children have persisting SE after receiving benzodiazepines,<sup>6,10</sup> yet there are few comparative data evaluating the medication options available. Phenytoin is reported as the second-line agent by most respondents in surveys of pediatric emergency medicine physicians<sup>57</sup> and neurologists.<sup>58</sup> Fosphenytoin is a prodrug of phenytoin, and although it may be administered more rapidly, it must then be converted to phenytoin internally, so they likely reach therapeutic concentrations in the brain in about the same time. The Neurocritical Care Society guideline considers phenytoin or fosphenytoin to be emergent treatment options, urgent treatment options, and refractory treatment options.<sup>4</sup> Cardiac arrhythmias are rare, especially with fosphenytoin, but may occur with both. Fosphenytoin is associated with less tissue injury if infiltration occurs. Both are considered focal anticonvulsants, and they may be ineffective in treating SE related to generalized epilepsy. There are numerous drug interactions due to strong hepatic induction and high protein binding.

Phenobarbital is often considered a third or fourth line drug in most pediatric SE pathways. The Neurocritical Care Society guideline considers phenobarbital to be an emergent treatment option and an urgent control treatment option.<sup>4</sup> Dosing is generally 20 mg/kg followed by another 5-10 mg/kg if needed. One study of 36 children with SE indicated that phenobarbital stopped seizures faster than a combination of diazepam and phenytoin and safety was similar,<sup>59</sup> and several reports have described the use of high-dose phenobarbital to control RSE and allow withdrawal of pharmacologic coma.<sup>60-62</sup> Phenobarbital may cause sedation, respiratory depression, and hypotension, so cardiovascular and respiratory monitoring is generally required. It is a hepatic enzyme inducer leading to drug interactions.

Valproate sodium is a broad-spectrum anticonvulsant and has been reported to be safe and highly effective in terminating SE and RSE. It is a broad-spectrum anticonvulsant with multiple mechanisms of action, including modulation of sodium and calcium channels and inhibitory GABA transmission.<sup>63</sup> Because it has mechanisms independent of GABA receptors, valproate may be effective later in RSE once GABA receptors have been targeted by other agents. The Neurocritical Care Society guideline considers valproate sodium to be an emergent treatment option, an urgent control treatment option, and a refractory treatment option.<sup>4</sup> Several studies and reports have reported that valproate sodium at doses of 20-40 mg/kg is effective in terminating RSE in children without adverse effects.<sup>64-68</sup> Black box warnings include hepatotoxicity (highest risk in children younger than 2 years, receiving anticonvulsant polytherapy,

and with suspected or known metabolic or mitochondrial disorders), pancreatitis, and teratogenicity. Other adverse effects include pancytopenia, thrombocytopenia, platelet dysfunction, hypersensitivity reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), and encephalopathy (with or without elevated ammonia). There are numerous drug interactions owing to strong hepatic inhibition.

Levetiracetam is a broad-spectrum anticonvulsant and there is increasing evidence that levetiracetam may be safe and effective for treating SE. The Neurocritical Care Society guideline considers levetiracetam to be an urgent therapy option.<sup>4</sup> Several observational studies in children have reported that levetiracetam may be safe and effective for managing SE and acute symptomatic seizures in children at doses of 20-60 mg/kg.<sup>69-73</sup> Levetiracetam has no hepatic metabolism, which may be beneficial in complex patients with liver dysfunction, metabolic disorders, or in those at risk for major drug interactions. In comparison with other intravenous anticonvulsants, levetiracetam has a low risk of sedation or cardiorespiratory depression. As levetiracetam clearance is dependent on renal function, maintenance dosage reduction is required in patients with renal impairment.

## Refractory Status Epilepticus

RSE is characterized by seizures that persist despite treatment with adequate doses of initial anticonvulsants. Definitions for RSE have varied in seizure durations (no time criteria, 30 minutes, 1 hour, or 2 hours) or lack of response to different numbers (2 or 3) and types of anticonvulsants. The Neurocritical Care Society guideline states that "patients who continue to experience either clinical or electrographic seizures after receiving adequate doses of an initial benzodiazepine followed by a second acceptable anticonvulsant will be considered refractory."<sup>4</sup> In contrast to prior definitions of RSE, there is no specific time that must elapse to define RSE, thereby emphasizing the importance of rapid sequential treatment. In the guideline, "refractory therapy" refers to anticonvulsants administered immediately if seizures persist after treatment with an urgent control therapy medication, and the guideline discusses that "the main decision point at this step is to consider repeat bolus of the urgent control anticonvulsant or to immediately initiate additional agents."<sup>4</sup> Additional urgent control anticonvulsants may be reasonable if they have not yet been tried or if the patient needs to be transferred or stabilized before administration of continuous infusions. However, if an initial urgent control medication fails to terminate seizures, then preparations should be initiated to achieve definitive seizure control with continuous infusions. Depending on RSE definitions and the cohorts described, RSE occurs in about 10%-40% of children<sup>11,12,74</sup> with SE. Studies in children have indicated that SE lasted more than 1 hour in 26%-45% of patients,<sup>75,76</sup> longer than 2 hours in 17%-25% of patients,<sup>76,77</sup> and longer than 4 hours in 10% of patients.<sup>76</sup>

In a subgroup of patients, RSE may last for weeks to months, despite treatment with multiple anticonvulsant medications. This lengthy course has been referred to as malignant RSE<sup>78</sup> or superrefractory SE.<sup>79,80</sup> Malignant RSE is associated with an infectious or inflammatory etiology, younger age, previous good health, and high morbidity and mortality.<sup>78,81,82</sup> It has also been referred to as de novo cryptogenic refractory multifocal SE,<sup>82</sup> new-onset RSE,<sup>81,83,84</sup> and FIRES.<sup>85-87</sup> Some of these entities in which RSE occurs in a previously healthy person with no identified cause except a recent infection may represent overlapping terms describing similar or identical entities.<sup>88</sup>

The management of RSE has been reviewed previously in children<sup>89-92</sup> and although there is variability in suggested pathways, all either administer additional anticonvulsants, such as phenytoin or fosphenytoin, phenobarbital, valproate sodium, or levetiracetam, or they proceed to pharmacologic coma induction with intravenous or inhaled medications. A survey of 60 experts in SE management conveyed that there was substantial variability in the selected medications which included phenytoin, levetiracetam, valproate, and midazolam.<sup>93</sup> Children with RSE should be treated in an ICU under the supervision of a neurologic and critical care team with experience in managing these patients. The Neurocritical Care Society guidelines recommend rapid advancement to pharmacologic coma induction rather than sequential trials of many urgent control anticonvulsants.<sup>4</sup>

Midazolam is a fast-acting benzodiazepine that rapidly penetrates the blood-brain barrier and has a short duration of action. Midazolam dosing usually involves an initial loading dose of 0.2 mg/kg followed by an infusion at 0.05-2 mg/kg/h titrated as needed to achieve clinical or electrographic seizure suppression or EEG burst suppression. If seizures persist, escalating dosing through additional boluses is needed to rapidly increase levels and terminate seizures. Increasing the infusion rate without bolus dosing would lead to very slow increase in serum levels, which is inconsistent with the goal of rapid seizure termination. A meta-analysis of 111 children indicated that midazolam was as effective as other coma-inducing medications and had lower mortality<sup>94</sup> and a multicenter, retrospective study suggested efficacy of both midazolam boluses and continuous infusion.<sup>13</sup> An open-label randomized study comparing midazolam and diazepam in 40 children indicated similar efficacy (86% and 89%), but midazolam was associated with higher recurrence (57% vs 16%) and higher mortality (38% vs 10.5%).<sup>95</sup> Studies describe breakthrough seizures and seizures on weaning in 25%-50% of children.

Pentobarbital is a barbiturate that may be used to treat RSE. Dosing usually involves an initial loading dose of 5-15 mg/kg (followed by another 5-10 mg/kg if needed) or by an infusion at 0.5-5 mg/kg/h titrated as needed to achieve seizure suppression or EEG burst suppression. If seizures persist, escalating dosing through additional boluses is needed to rapidly increase levels and terminate seizures. Increasing the infusion rate without additional bolus dose administration would lead to very slow increases in pentobarbital levels, which is inconsistent with the goal of rapid

seizure termination. One case series of 26 children who received pentobarbital for RSE years provided a loading dose of 5 mg/kg followed by an infusion of 1-3 mg/kg/h. Efficacy was 74% but 22% had relapse of seizures upon pentobarbital weaning.<sup>96</sup> A case series of 30 patients who received pentobarbital for RSE described sustained burst suppression without relapse in 33%.<sup>97</sup> Adverse effects include respiratory depression, hypotension, cardiac depression, paralytic ileus, infection, and suppression of brainstem reflexes. Anesthetics such as isoflurane are effective in inducing a burst suppression pattern and terminating seizures, but only case reports are available.<sup>98,99</sup>

Management of a RSE patient with volatile anesthetics should be performed with the support and guidance of an anesthesiologist. Propofol may also be used to terminate seizures, but it is rarely used in children owing to its Food and Drug Administration black box warning because of the risk of propofol infusion syndrome.

Patients treated with continuous infusions or inhaled anesthetics require intensive monitoring. All patients need invasive continuous mechanical ventilation for both airway protection and to maintain appropriate oxygenation and ventilation as medications are titrated. Central venous and arterial access should be considered as these patients require frequent laboratory sampling and are at high risk for developing hypotension requiring vasopressor or inotropic support. Because high-dose sedatives and anesthetics can blunt the shivering response and endogenous thermoregulation, continuous core temperature monitoring should be used with external thermoregulation when needed. Patients should undergo continued evaluation for the development of lactic acidosis, anemia, thrombocytopenia, and end-organ dysfunction such as acute liver or renal injury. Finally, these patients are at increased risk of secondary infections owing to indwelling catheters (central catheters, endotracheal tubes, and Foley catheters) as well as some medications (pentobarbital). Clinicians should maintain a high index of suspicion for infection as hypotension and hypothermia can be perceived to be because of seizure treatment, when they may be because of the onset of sepsis.

When coma-inducing agents are used, it remains unclear whether the treatment goal should be termination of seizures, burst suppression, or complete suppression of EEG activity. The Neurocritical Care Society guideline states that "dosing of continuous infusions anticonvulsants for RSE should be titrated to cessation of electrographic seizures or burst suppression."<sup>4</sup> Patients may have seizures, even when the interictal background is primarily a burst suppression pattern or even complete suppression, so this level of suppression does not guarantee seizure suppression. Adult reports comparing treatment goals of burst suppression vs seizure termination are inconclusive,<sup>100-102</sup> and there are no data in children.

It remains unclear how long the patient should be maintained in pharmacologic coma. The Neurocritical Care Society guideline states that "a period of 24-48 hours of electrographic control is recommended before slow withdrawal of continuous infusion anticonvulsants for RSE"<sup>4</sup> and

a survey of experts in SE management across all age groups reported they would continue pharmacologic coma for 24 hours.<sup>93</sup> Electrographic or electroclinical seizures frequently recur during the weaning of it medications,<sup>95,96,103,104</sup> indicating that it should be considered as a temporizing measure, and during this period other anticonvulsants should be initiated, which may provide seizure control as coma-inducing medications are weaned. Often, coma-inducing medications are weaned over 1-2 days, although this is not evidence based. If definite seizures occur, reinitiating pharmacologic coma may provide additional time to adjust other anticonvulsants. A survey of experts on SE management reported that if seizures recurred during weaning of the pharmacologic coma, they would reintroduce it for 24-48 hours.<sup>93</sup> However, after several weaning attempts, reinitiating it for recurrent seizures may not be optimal. First, continued pharmacologic coma use is associated with adverse effects. Second, in a report of prognosis of 22 children with RSE, all survivors had intractable epilepsy and many children had persisting seizures during or shortly after weaning of antiseizure medications.<sup>105</sup> As future seizures are so likely, some seizures may be tolerated during weaning from pharmacologic coma.

Case reports and series have described several add-on medications, and other techniques have been reported useful in reducing seizure recurrence as pharmacologic coma is weaned, but there are no large studies. These options include topiramate, ketamine, pyridoxine, the ketogenic diet, epilepsy surgery, immunomodulation, hypothermia, and electroconvulsive therapy.

Topiramate is a broad-spectrum anticonvulsant with several mechanisms of action and may be logical to use in RSE once GABA receptors have been targeted by other medications. Although not available in an intravenous form, tablets can be crushed for use with feeding tubes. Studies have not evaluated topiramate for early SE, but reports suggest it may be a useful add-on medication for RSE.<sup>62,106-108</sup> Dosing is varied in these reports, but often starts at 1-5 mg/kg/d with escalation to 20-25 mg/kg/d. Topiramate is a carbonic anhydrase inhibitor and may result in metabolic acidosis by preventing bicarbonate formation. Rare adverse reactions include nephrolithiasis, pancreatitis, acute angle closure glaucoma, and oligohydrosis with resulting hyperthermia.

Ketamine is a noncompetitive NMDA-type glutamate receptor antagonist that may be effective in later stages of RSE as it acts independently of GABA-related mechanisms. Only case reports and series are available, reporting 0.5-2 mg/kg loading doses followed by continuous infusions. The largest case series described 9 children with RSE with ketamine administered at a median of 6 days of RSE at a median dose of 40 mcg/kg/min. RSE was controlled in 66% and no major adverse effects were reported.<sup>109</sup> Ketamine's sympathomimetic properties may produce hypertension and tachycardia.

Pyridoxine-dependent seizures are typically related to a rare autosomal recessive mutation in the ALDH7A1 gene which encodes antiquitin. Although generally considered in neonates with seizures, there have been reports of cases in

older patients including infants and even adults with SE controlled by pyridoxine.<sup>110-114</sup> The diagnosis of pyridoxine-responsive seizures is made when administration of intravenous pyridoxine (100 mg given for 1-5 doses) terminates seizures, typically within hours of administration. Pyridoxine responsiveness may occur in children with ALDH7A1 mutations, pyridoxine 5'-phosphate oxidase deficiency, hypophosphatasia, nutritional pyridoxine deficiency, and some children with idiopathic epilepsy. Some children who do not respond to pyridoxine may respond to pyridoxal-5-phosphate (PLP, also known as P5P, 50-100 mg/kg/d) or to folinic acid (3-5 mg/kg/d).<sup>115,116</sup> Diagnosis of pyridoxine-dependent epilepsy may be established by evaluating for elevated urinary alpha-aminoadipic semi-aldehyde or a specific marker on neurotransmitter testing. For patients who have responded to therapy testing can be performed for mutations in known genes.<sup>117</sup> Other vitamin response epilepsies typically present during infancy, but late-onset pyridoxine 5'-phosphate oxidase deficiency responding only to PLP and late-onset biotinidase deficiency responding to biotin have both been described.<sup>118,119</sup> Thus, a trial of PLP or biotin could be considered in RSE.

The ketogenic diet is a high-fat, low-carbohydrate diet that can be administered by parenteral nutrition or intravenously. It is considered the treatment of choice for GLUT-1 transporter deficiency and pyruvate dehydrogenase deficiency, although it is contraindicated in patients with porphyria, pyruvate carboxylase deficiency, disorders of fatty acid oxidation and metabolism, and some other metabolic disorders. Screening laboratory tests include serum acylcarnitine profile, amino acids, lactate, ammonia, complete blood count, electrolytes, liver function tests, and urine organic acids.<sup>120,121</sup> Implementation is complex and multiple adverse effects may occur, necessitating an experienced team.<sup>122</sup> Adverse effects include hypoglycemia, metabolic acidosis, hypertriglyceridemia, gastroesophageal reflux, emesis, constipation, nephrolithiasis, esophagitis, renal tubular acidosis, hepatitis, lipoid pneumonia, pancreatitis, and metabolic abnormalities. Several case reports and series describe benefit with the ketogenic diet, including efficacy in 7 of 9 patients with FIRES in a mean of 5 days after starting the diet.<sup>123</sup> A literature review summarized 32 reported cases in which children and adults with SE were treated with dietary therapy and reported that 78% became seizure-free, with a response usually evident in 7-10 days.<sup>122</sup>

Immunomodulatory therapies may be useful in the context of cryptogenic RSE or when there is a confirmed autoimmune or inflammatory etiology, such as Rasmussen encephalitis, central nervous system vasculitis, NMDAR encephalitis, or Hashimoto encephalopathy. Though there have been no controlled studies of the use of corticosteroids, intravenous immunoglobulin (IVIG), or plasma exchange for RSE, small observational studies have described benefit. For example, in a case series of 5 adults with cryptogenic RSE, the 3 patients with good outcomes were all treated with early immunotherapy.<sup>124</sup>

When steroids are used for RSE, initial treatment often consists of intravenous methylprednisolone at a dose of

30 mg/kg/d (maximum of 1 g) for 3 days. If infection is being considered as an etiology for RSE, infectious disease specialists should be involved before initiation of steroids, and patients should be covered with appropriate antiviral and antibiotic agents until infectious studies have resulted. IVIG has also been used in refractory epilepsy if an underlying autoimmune etiology is suspected.<sup>124,125</sup> This therapy is typically employed if a patient has an inadequate response to steroids or if steroids are contraindicated. Standard dosage for IVIG is 2 g/kg divided over 2-5 days. All diagnostic serum antibody testing should be obtained before initiation of IVIG. Although plasma exchange is more invasive than intravenous administration of methylprednisolone and IVIG as it requires placement of an indwelling catheter, patients with RSE have reported benefit from this treatment.<sup>126,127</sup> Although the mechanism of action of plasma exchange is likely multifactorial, it is thought to have an effect by removing pathogenic antibodies and immune complexes from blood and by modulating proinflammatory cytokines. A typical course of plasma exchange consists of 5-7 exchanges over 14 days. A patient's coagulation factors, electrolytes, and fluid balance must be closely monitored over this time period and levels of antiepileptic medications should be checked regularly to ensure that they remain therapeutic. As with IVIG, all diagnostic serum antibody testing should be obtained before initiation of plasma exchange.

If an autoimmune or paraneoplastic etiology is confirmed as the cause for RSE and a patient does not respond to initial treatment with methylprednisolone, IVIG, or plasma exchange, second-line treatment with rituximab or cyclophosphamide should be considered. As these second-line therapies are associated with potentially severe adverse effects, clinical response should be closely monitored after initiation of these treatments to help determine whether subsequent maintenance of immunosuppression is warranted. Although response to immunotherapy can support a diagnosis of autoimmune epilepsy, direct benefit is often difficult to prove as patients are often concurrently being treated with conventional antiepileptic agents.

Case reports and series have reported efficacy of a variety of surgical procedures for many types of lesions when all seizures have onset in an identifiable location. One case series of 15 children with RSE who underwent surgical procedures reported that all had seizure control ranging from seizure freedom to substantial reductions, allowing transition out of the ICU.<sup>128</sup> Vagus nerve stimulation has been reported to be effective in several case reports, but efficacy generally occurs over a prolonged period.

When used as a neuroprotective strategy for multiple types of brain injury, therapeutic hypothermia may reduce many destructive processes due to excitotoxicity, neuroinflammation, apoptosis, free radical production, seizures, and blood-brain barrier disruption. Only case reports and small case series have described the use of therapeutic hypothermia for SE and some indicate that 1-5 days of hypothermia to 32°C-36°C may terminate seizures and that some patients do not have seizure recurrence on rewarming.<sup>129,130</sup>

RSE is considered an indication for electroconvulsive therapy by the American Psychiatric Association Task Force Report.<sup>131</sup> Only case reports and small series are available, but they indicate some patients have temporary improvement and rare patients have full functional recovery.<sup>132</sup> Cardiovascular conditions are a relative contraindication, and in some patients, electroconvulsive therapy may also provoke SE.

## Conclusions

SE is a common neurologic emergency. Rapid efforts are needed to manage systemic complications, identify and manage precipitating conditions, and terminate seizures. A predetermined management plan that stresses urgent progression through appropriately dosed anticonvulsants may avoid delays. Although data are limited regarding RSE management, a logical stepwise approach using available options is needed. Pharmacologic coma induction offers a window to identify and manage precipitant etiologies and put in place antiseizure strategies aiming to provide seizure control during pharmacologic coma weaning. Although studies have compared benzodiazepines and administration strategies, there have been few studies of medications used when seizures persist after administration benzodiazepines. However, research consortia are growing to identify and develop evidence-based interventions to improve the care of children with SE.<sup>133</sup>

## References

- Chin RF, Neville BG, Peckham C, et al: Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: Prospective population-based study. *Lancet* 368:222-229, 2006
- Commission on Epidemiology and Prognosis, International League Against Epilepsy: Guidelines for epidemiologic studies on epilepsy. *Epilepsia* 34:592-596, 1993
- Shinnar S, Berg AT, Moshe SL, et al: How long do new-onset seizures in children last? *Ann Neurol* 49:659-664, 2001
- Brophy GM, Bell R, Claassen J, et al: Guidelines for the evaluation and management of status epilepticus. *Neurocrit Care* 17:3-23, 2012
- Tobias JD, Berkenbosch JW: Management of status epilepticus in infants and children prior to pediatric ICU admission: Deviations from the current guidelines. *South Med J* 101:268-272, 2008
- Lewena S, Pennington V, Acworth J, et al: Emergency management of pediatric convulsive status epilepticus: A multicenter study of 542 patients. *Pediatr Emerg Care* 25:83-87, 2009
- Chin RF, Verhulst L, Neville BG, et al: Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. *J Neurol Neurosurg Psychiatry* 75:1584-1588, 2004
- Tirupathi S, McMenamin JB, Webb DW: Analysis of factors influencing admission to intensive care following convulsive status epilepticus in children. *Seizure* 18:630-633, 2009
- Chin RF, Neville BG, Peckham C, et al: Treatment of community-onset, childhood convulsive status epilepticus: A prospective, population-based study. *Lancet Neurol* 7:696-703, 2008
- Lambrechtsen FA, Buchhalter JR: Aborted and refractory status epilepticus in children: A comparative analysis. *Epilepsia* 49:615-625, 2008
- Lewena S, Young S: When benzodiazepines fail: How effective is second line therapy for status epilepticus in children? *Emerg Med Australas* 18:45-50, 2006
- Eriksson K, Metsaranta P, Huhtala H, et al: Treatment delay and the risk of prolonged status epilepticus. *Neurology* 65:1316-1318, 2005
- Hayashi K, Osawa M, Aihara M, et al: Efficacy of intravenous midazolam for status epilepticus in childhood. *Pediatr Neurol* 36:366-372, 2007
- Shorvon S, Baulac M, Cross H, et al: The drug treatment of status epilepticus in Europe: Consensus document from a workshop at the first London Colloquium on Status Epilepticus. *Epilepsia* 49:1277-1286, 2008
- Abend NS, Loddenkemper T: Pediatric status epilepticus management. *Curr Opin Pediatr* 26:668-674, 2014
- Abend NS, Loddenkemper T: Management of pediatric status epilepticus. *Curr Treat Options Neurol* 16:301, 2014
- Abend NS, Gutierrez-Colina AM, Dlugos DJ: Medical treatment of pediatric status epilepticus. *Semin Pediatr Neurol* 17:169-175, 2010
- Hussain N, Appleton R, Thorburn K: Aetiology, course and outcome of children admitted to paediatric intensive care with convulsive status epilepticus: A retrospective 5-year review. *Seizure* 16:305-312, 2007
- Singh RK, Stephens S, Berl MM, et al: Prospective study of new-onset seizures presenting as status epilepticus in childhood. *Neurology* 74:636-642, 2010
- Nishiyama I, Ohtsuka Y, Tsuda T, et al: An epidemiological study of children with status epilepticus in Okayama, Japan. *Epilepsia* 48:1133-1137, 2007
- Berg AT, Shinnar S, Testa FM, et al: Status epilepticus after the initial diagnosis of epilepsy in children. *Neurology* 63:1027-1034, 2004
- Berg AT, Shinnar S, Levy SR, et al: Status epilepticus in children with newly diagnosed epilepsy. *Ann Neurol* 45:618-623, 1999
- Riviello JJ, Ashwal S, Hirtz D, et al: Practice parameter: Diagnostic assessment of the child with status epilepticus (an evidence-based review). *Neurology* 67:1542-1550, 2006
- Waternberg N, Segal G: A suggested approach to the etiologic evaluation of status epilepticus in children: What to seek after the usual causes have been ruled out. *J Child Neurol* 25:203-211, 2010
- Abend NS, Gutierrez-Colina AM, Topjian AA, et al: Nonconvulsive seizures are common in critically ill children. *Neurology* 76:1071-1077, 2011
- Abend NS, Arndt DH, Carpenter JL, et al: Electrographic seizures in pediatric ICU patients: Cohort study of risk factors and mortality. *Neurology* 81:383-391, 2013
- Sanchez Fernandez I, Abend NS, Arndt DH, et al: Electrographic seizures after convulsive status epilepticus in children and young adults. A retrospective multicenter study. *J Pediatr* 164:339-346, 2014
- Kirkham FJ, Wade AM, McElduff F, et al: Seizures in 204 comatose children: Incidence and outcome. *Intensive Care Med* 38:853-862, 2012
- Topjian AA, Gutierrez-Colina AM, Sanchez SM, et al: Electrographic status epilepticus is associated with mortality and worse short-term outcome in critically ill children. *Crit Care Med* 31:215-223, 2013
- Wagenman KL, Blake TP, Sanchez SM, et al: Electrographic status epilepticus and long-term outcome in critically ill children. *Neurology* 82:396-404, 2014
- Payne ET, Zhao XY, Frndova H, et al: Seizure burden is independently associated with short term outcome in critically ill children. *Brain* 137:1429-1438, 2014
- Neligan A, Shorvon SD: Frequency and prognosis of convulsive status epilepticus of different causes: A systematic review. *Arch Neurol* 67:931-940, 2010
- Saz EU, Karapinar B, Ozcetin M, et al: Convulsive status epilepticus in children: Etiology, treatment protocol and outcome. *Seizure* 20:115-118, 2011
- Glaser CA, Gilliam S, Honarmand S, et al: Refractory status epilepticus in suspect encephalitis. *Neurocrit Care* 9:74-82, 2008
- Venkatesan A, Tunkel AR, Bloch KC, et al: Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium. *Clin Infect Dis* 57:1114-1128, 2013
- McGuire JL, Green AM: Central nervous system infections In: in Abend NS, Helfaer MA (eds.), *Pediatric Neurocritical Care*. New York, NY; Demos, pp 267-336, 2013
- Dalmay J, Tuzun E, Wu HY, et al: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Ann Neurol* 61:25-36, 2007
- Davis R, Dalmay J: Autoimmunity, seizures, and status epilepticus. *Epilepsia* 54:46-49, 2013 (suppl 6)

39. Bien CG, Vincent A, Barnett MH, et al: Immunopathology of autoantibody-associated encephalitides: Clues for pathogenesis. *Brain* 135:1622-1638, 2012
40. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al: Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. *Neurology* 77:1698-1701, 2011
41. Florance NR, Davis RL, Lam C, et al: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. *Ann Neurol* 66:11-18, 2009
42. Titulaer MJ, McCracken L, Gabilondo I, et al: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. *Lancet Neurol* 12:157-165, 2013
43. Haberlandt E, Bast T, Ebner A, et al: Limbic encephalitis in children and adolescents. *Arch Dis Child* 96:186-191, 2011
44. Suleiman J, Wright S, Gill D, et al: Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. *Epilepsia* 54:2091-2100, 2013
45. Kruer MC, Hoefberger R, Lim KY, et al: Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: The first pediatric case of gamma-aminobutyric acid type B receptor autoimmunity. *J Am Med Assoc Neurol* 71:620-623, 2014
46. Petit-Pedrol M, Armanque T, Peng X, et al: Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA<sub>A</sub> receptor: A case series, characterisation of the antigen, and analysis of the effects of antibodies. *Lancet Neurol* 13:276-286, 2014
47. Gable MS, Sheriff H, Dalmau J, et al: The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. *Clin Infect Dis* 54:899-904, 2012
48. Granerod J, Ambrose HE, Davies NW, et al: Causes of encephalitis and differences in their clinical presentations in England: A multi-centre, population-based prospective study. *Lancet Infect Dis* 10:835-844, 2010
49. Varadkar S, Bien CG, Kruse CA, et al: Rasmussen's encephalitis: Clinical features, pathobiology, and treatment advances. *Lancet Neurol* 13:195-205, 2014
50. Tsai MH, Lee LH, Chen SD, et al: Complex partial status epilepticus as a manifestation of Hashimoto's encephalopathy. *Seizure* 16:713-716, 2007
51. Dravet C, Oguni H: Dravet syndrome (severe myoclonic epilepsy in infancy). *Handb Clin Neurol* 111:627-633, 2013
52. Wolf NI, Rahman S, Schmitt B, et al: Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. *Epilepsia* 50:1596-1607, 2009
53. Appenzeller S, Helbig I, Stephani U, et al: Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations. *Dev Med Child Neurol* 54:1144-1148, 2012
54. Lemke JR, Riesch E, Scheurenbrand T, et al: Targeted next generation sequencing as a diagnostic tool in epileptic disorders. *Epilepsia* 53:1387-1398, 2012
55. Allen AS, Berkovic SF, Cossette P, et al: De novo mutations in epileptic encephalopathies. *Nature* 501:217-221, 2013
56. Chamberlain JM, Okada P, Holsti M, et al: Lorazepam vs diazepam for pediatric status epilepticus: A randomized clinical trial. *J Am Med Assoc* 311:1652-1660, 2014
57. Babl FE, Sheriff N, Borland M, et al: Emergency management of paediatric status epilepticus in Australia and New Zealand: Practice patterns in the context of clinical practice guidelines. *J Paediatr Child Health* 45:541-546, 2009
58. Claassen J, Hirsch LJ, Mayer SA: Treatment of status epilepticus: A survey of neurologists. *J Neurol Sci* 211:37-41, 2003
59. Shaner DM, McCurdy SA, Herring MO, et al: Treatment of status epilepticus: A prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. *Neurology* 38:202-207, 1988
60. Crawford TO, Mitchell WG, Fishman LS, et al: Very-high-dose phenobarbital for refractory status epilepticus in children. *Neurology* 38:1035-1040, 1988
61. Wilmshurst JM, van der Walt JS, Ackermann S, et al: Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. *J Paediatr Child Health* 46:17-22, 2010
62. Lin JJ, Lin KL, Wang HS, et al: Effect of topiramate, in combination with lidocaine, and phenobarbital, in acute encephalitis with refractory repetitive partial seizures. *Brain Dev* 31:605-611, 2009
63. Rogawski MA, Loscher W: The neurobiology of antiepileptic drugs. *Nat Rev Neurosci* 5:553-564, 2004
64. Yu KT, Mills S, Thompson N, et al: Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. *Epilepsia* 44:724-726, 2003
65. Überall MA, Trollmann R, Wunsiedler U, et al: Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. *Neurology* 54:2188-2189, 2000
66. Mehta V, Singhi P, Singhi S: Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: A randomized controlled trial. *J Child Neurol* 22:1191-1197, 2007
67. Campistol J, Fernandez A, Ortega J: Status epilepticus in children. Experience with intravenous valproate. Update of treatment guidelines. *Rev Neurol* 29:359-365, 1999
68. Hovinga CA, Chicella MF, Rose DF, et al: Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. *Ann Pharmacother* 33:579-584, 1999
69. Abend NS, Chapman KE, Gallentine WB, et al: Electroencephalographic monitoring in the pediatric intensive care unit. *Curr Neurol Neurosci Rep* 13:330, 2013
70. Reiter PD, Huff AD, Knupp KG, et al: Intravenous levetiracetam in the management of acute seizures in children. *Pediatr Neurol* 43:117-121, 2010
71. Abend NS, Monk HM, Licht DJ, et al: Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. *Pediatr Crit Care Med* 10:505-510, 2009
72. Goraya JS, Khurana DS, Valencia I, et al: Intravenous levetiracetam in children with epilepsy. *Pediatr Neurol* 38:177-180, 2008
73. Gallentine WB, Hunnicutt AS, Husain AM: Levetiracetam in children with refractory status epilepticus. *Epilepsy Behav* 14:215-218, 2009
74. Brevoord JC, Joosten KF, Arts WF, et al: Status epilepticus: Clinical analysis of a treatment protocol based on midazolam and phenytoin. *J Child Neurol* 20:476-481, 2005
75. Maytal J, Shinnar S, Moshe SL, et al: Low morbidity and mortality of status epilepticus in children. *Pediatrics* 83:323-331, 1989
76. Dunn DW: Status epilepticus in children: Etiology, clinical features, and outcome. *J Child Neurol* 3:167-173, 1988
77. Eriksson KJ, Koivikko MJ: Status epilepticus in children: Aetiology, treatment, and outcome. *Dev Med Child Neurol* 39:652-658, 1997
78. Holtkamp M, Othman J, Buchheim K, et al: A "malignant" variant of status epilepticus. *Arch Neurol* 62:1428-1431, 2005
79. Shorvon S, Ferlisi M: The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. *Brain* 134:2802-2818, 2011
80. Shorvon S: Super-refractory status epilepticus: An approach to therapy in this difficult clinical situation. *Epilepsia* 52:53-56, 2011 (suppl 8)
81. Wilder-Smith EP, Lim EC, Teoh HL, et al: The NORSE (new-onset refractory status epilepticus) syndrome: Defining a disease entity. *Ann Acad Med Singapore* 34:417-420, 2005
82. Van Lierde I, Van Paesschen W, Dupont P, et al: De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: A review of six cases. *Acta Neurol Belg* 103:88-94, 2003
83. Rathakrishnan R, Wilder-Smith EP: New onset refractory status epilepticus (NORSE). *J Neurol Sci* 284:220, 2009. [author reply -1]
84. Costello DJ, Kilbride RD, Cole AJ: Cryptogenic new onset refractory status epilepticus (NORSE) in adults—Infectious or not? *J Neurol Sci* 277:26-31, 2009
85. Kramer U, Chi CS, Lin KL, et al: Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome: A multi-center study on 77 children. *Epilepsia* 2011

86. Kramer U, Shorer Z, Ben-Zeev B, et al: Severe refractory status epilepticus owing to presumed encephalitis. *J Child Neurol* 20:184-187, 2005
87. van Baalen A, Hausler M, Boor R, et al: Febrile infection-related epilepsy syndrome (FIRES): A nonencephalitic encephalopathy in childhood. *Epilepsia* 51:1323-1328, 2010
88. Ismail FY, Kossoff EH: AERRPS, DESC, NORSE, FIRES: Multi-labeling or distinct epileptic entities? *Epilepsia* 52:e185-e198, 2011
89. Abend NS, Dlugos DJ: Treatment of refractory status epilepticus: Literature review and a proposed protocol. *Pediatr Neurol* 38:377-390, 2008
90. Owens J: Medical management of refractory status epilepticus. *Semin Pediatr Neurol* 17:176-181, 2010
91. Wheless JW: Treatment of refractory convulsive status epilepticus in children: Other therapies. *Semin Pediatr Neurol* 17:190-194, 2010
92. Wilkes R, Tasker RC: Pediatric intensive care treatment of uncontrolled status epilepticus. *Crit Care Clin* 29:239-257, 2013
93. Riviello JJ Jr, Claassen J, LaRoche SM, et al: Treatment of status epilepticus: An international survey of experts. *Neurocrit Care* 18:193-200, 2013
94. Gilbert DL, Gartside PS, Glauser TA: Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children: A meta-analysis. *J Child Neurol* 14:602-609, 1999
95. Singhi S, Murthy A, Singhi P, et al: Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. *J Child Neurol* 17:106-110, 2002
96. Kim SJ, Lee DY, Kim JS: Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. *Pediatr Neurol* 25:217-220, 2001
97. Barberio M, Reiter PD, Kaufman J, et al: Continuous infusion pentobarbital for refractory status epilepticus in children. *J Child Neurol* 27:721-726, 2012
98. Kofke WA, Young RS, Davis P, et al: Isoflurane for refractory status epilepticus: A clinical series. *Anesthesiology* 71:653-659, 1989
99. Mirsattari SM, Sharpe MD, Young GB: Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. *Arch Neurol* 61:1254-1259, 2004
100. Rossetti AO, Logroscino G, Bromfield EB: Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. *Arch Neurol* 62:1698-1702, 2005
101. Krishnamurthy KB, Drislane FW: Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. *Epilepsia* 40:759-762, 1999
102. Claassen J, Hirsch LJ, Emerson RG, et al: Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: A systematic review. *Epilepsia* 43:146-153, 2002
103. Morrison G, Gibbons E, Whitehouse WP: High-dose midazolam therapy for refractory status epilepticus in children. *Intensive Care Med* 32:2070-2076, 2006
104. Koul R, Chacko A, Javed H, et al: Eight-year study of childhood status epilepticus: Midazolam infusion in management and outcome. *J Child Neurol* 17:908-910, 2002
105. Sahin M, Menache CC, Holmes GL, et al: Outcome of severe refractory status epilepticus in children. *Epilepsia* 42:1461-1467, 2001
106. Kahriman M, Minecan D, Kutluay E, et al: Efficacy of topiramate in children with refractory status epilepticus. *Epilepsia* 44:1353-1356, 2003
107. Perry MS, Holt PJ, Sladky JT: Topiramate loading for refractory status epilepticus in children. *Epilepsia* 47:1070-1071, 2006
108. Blumkin L, Lerman-Sagie T, Hourii T, et al: Pediatric refractory partial status epilepticus responsive to topiramate. *J Child Neurol* 20:239-241, 2005
109. Rosati A, L'Erario M, Ilvento L, et al: Efficacy and safety of ketamine in refractory status epilepticus in children. *Neurology* 79:2355-2358, 2012
110. Yoshii A, Takeoka M, Kelly PJ, et al: Focal status epilepticus as atypical presentation of pyridoxine-dependent epilepsy. *J Child Neurol* 20:696-698, 2005
111. Goutieres F, Aicardi J: Atypical presentations of pyridoxine-dependent seizures: A treatable cause of intractable epilepsy in infants. *Ann Neurol* 17:117-120, 1985
112. Chou ML, Wang HS, Hung PC, et al: Late-onset pyridoxine-dependent seizures: Report of two cases. *Zhonghua Minguo Xiao Er Ke Yi Xue Hui Za Zhi* 36:434-437, 1995
113. Kluger G, Blank R, Paul K, et al: Pyridoxine-dependent epilepsy: Normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness. *Neuropediatrics* 39:276-279, 2008
114. Russell KE, Mulligan SR, Mallory LA: Diagnosis of pyridoxine-dependent seizures in a nineteen-year-old patient. *Pediatr Neurol* 47:141-143, 2012
115. Wang HS, Kuo MF, Chou ML, et al: Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. *Arch Dis Child* 90:512-515, 2005
116. Ficioglu C, Bearden D: Isolated neonatal seizures: When to suspect inborn errors of metabolism. *Pediatr Neurol* 45:283-291, 2011
117. Yeghiazaryan NS, Zara F, Capovilla G, et al: Pyridoxine-dependent epilepsy: An under-recognised cause of intractable seizures. *J Paediatr Child Health* 48:E113-E115, 2012
118. Joshi SN, Fathalla M, Koul R, et al: Biotin responsive seizures and encephalopathy due to biotinidase deficiency. *Neurol India* 58:323-324, 2010
119. Agadi S, Quach MM, Haneef Z: Vitamin-responsive epileptic encephalopathies in children. *Epilepsy Res Treat* 2013:510-529, 2013
120. Cervenka MC, Kossoff EH: Dietary treatment of intractable epilepsy. *Continuum (Minneapolis)* 19:756-766, 2013
121. Nordli DR, De Vivo DC: *The Ketogenic Diet*. In: Wyllie E (ed.), *Wyllie's Treatment of Epilepsy*, ed 5 Philadelphia, PA: Lippincott, Williams & Wilkins, pp 790-796, 2011
122. Kossoff EH, Nabbout R: Use of dietary therapy for status epilepticus. *J Child Neurol* 28:1049-1051, 2013
123. Nabbout R, Mazzuca M, Hubert P, et al: Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). *Epilepsia* 51:2033-2037, 2010
124. Gall CR, Jumma O, Mohanraj R: Five cases of new onset refractory status epilepticus (NORSE) syndrome: Outcomes with early immunotherapy. *Seizure* 22:217-220, 2013
125. Geva-Dayana K, Shorer Z, Menascu S, et al: Immunoglobulin treatment for severe childhood epilepsy. *Pediatr Neurol* 46:375-381, 2012
126. Gedik AH, Demirkol D, Tatli B, et al: Therapeutic plasma exchange for malignant refractory status epilepticus: A case report. *Pediatr Neurol* 50:407-410, 2014
127. Bektas O, Yilmaz A, Kendirli T, et al: Hashimoto encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis. *Pediatr Neurol* 46:132-135, 2012
128. Bhatia S, Ahmad F, Miller I, et al: Surgical treatment of refractory status epilepticus in children. *J Neurosurg Pediatr* 12:360-366, 2013
129. Guilliams K, Rosen M, Buttram S, et al: Hypothermia for pediatric refractory status epilepticus. *Epilepsia* 54:1586-1594, 2013
130. Lin JJ, Lin KL, Hsia SH, et al: Therapeutic hypothermia for febrile infection-related epilepsy syndrome in two patients. *Pediatr Neurol* 47:448-450, 2012
131. Weiner RD, Coffet CE, Fochtmann L: *The Practice of ECT: Recommendations for Treatment, Training and Privileging*, ed 2 Washington, DC, American Psychiatric Press, 2001
132. Lambrecq V, Villega F, Marchal C, et al: Refractory status epilepticus: Electroconvulsive therapy as a possible therapeutic strategy. *Seizure* 21:661-664, 2012
133. Sanchez Fernandez I, Abend NS, Agadi S, et al: Gaps and opportunities in refractory status epilepticus research in children: A multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG). *Seizure* 23:87-97, 2014